Figure 2.
Clinical courses of individual patients. Clinical courses are shown from the time of CARTi for patients who received CARTr for peripheral BCR followed by CR (A) or NR (B), and for patients who received CARTr for CD19+ hematogones followed by CR (C) or NR (D). (E) Clinical courses are shown from the time of CARTr for patients reinfused for CD19+ MRD/relapse. Data shown include duration of CR with BCA or BCR, duration of CR after HSCT or other alternative therapy, time to reinfusion(s), time to relapse denoted as CD19+ or CD19−, and time to death. BCA, B cell aplasia; BCR, B cell recovery; CR, complete response; HSCT, hematopoietic stem cell transplantation; NR, no response.

Clinical courses of individual patients. Clinical courses are shown from the time of CARTi for patients who received CARTr for peripheral BCR followed by CR (A) or NR (B), and for patients who received CARTr for CD19+ hematogones followed by CR (C) or NR (D). (E) Clinical courses are shown from the time of CARTr for patients reinfused for CD19+ MRD/relapse. Data shown include duration of CR with BCA or BCR, duration of CR after HSCT or other alternative therapy, time to reinfusion(s), time to relapse denoted as CD19+ or CD19, and time to death. BCA, B cell aplasia; BCR, B cell recovery; CR, complete response; HSCT, hematopoietic stem cell transplantation; NR, no response.

Close Modal

or Create an Account

Close Modal
Close Modal